Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 174

Sort by

Sort Order Select

Journal Articles

Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial

Blood (2025) 146 (23): 2758–2764.

https://doi.org/10.1182/blood.2025028823

Published: 2025

Includes: Supplemental data

Journal Articles

Final efficacy results of the real-life ambispective urban study on frontline obinutuzumab-based immunochemotherapy for advanced follicular lymphoma

Antonio Pinto, Marco Caltagirone, Daniela Facchinello, Joana Parreira, Caterina Patti, Elsa Pennese, Sonya De Lorenzo, Vincenzo Pavone, Marta Coscia, Annalisa Chiarenza, Luca Arcaini, Pier Luigi Zinzani, Marco Ladetto, Giuseppe Gritti

Blood (2025) 146 (Supplement 1): 5366.

https://doi.org/10.1182/blood-2025-5366

Published: 2025

Journal Articles

Increased incidence of secondary malignancies after autologous stem cell transplantation in follicular lymphoma patients: Long-term results of the FIL-FLAZ12 Phase III randomized trial

Blood (2025) 146 (Supplement 1): 5364.

https://doi.org/10.1182/blood-2025-5364

Published: 2025

Journal Articles

TP53 mutations in paired bone marrow and cell-free DNA samples of patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance prospectively enrolled in the FIL_biowm study of fondazione italiana linfomi

Blood (2025) 146 (Supplement 1): 5318.

https://doi.org/10.1182/blood-2025-5318

Published: 2025

Journal Articles

Morphology guided spatial transcriptomics to study topography of Hodgkin reed sternberg cells interaction with tumor microenvironment and its impact in defining risk of progression in classical Hodgkin lymphoma.

Benedetta Donati, Tanja Lazic, Riccardo Valli, Rexhep Durmo, Attilio Gennaro, Cristian Ascione, Pierluigi Di Chiaro, Alessia Ruffini, Manuel Gotti, Luca Arcaini, Erica Travaglino, Marco Paulli, Francesco Merli, Alessia Ciarrocchi, Stefano Luminari

Blood (2025) 146 (Supplement 1): 5315.

https://doi.org/10.1182/blood-2025-5315

Published: 2025

Journal Articles

EO2463 (EO) peptide immunotherapy combined with rituximab (R) for first-line treatment of low-tumor burden follicular lymphoma (FL): A feasibility evaluation in Study EONHL1-20/sidney (NCT04669171)

Blood (2025) 146 (Supplement 1): 3594.

https://doi.org/10.1182/blood-2025-3594

Published: 2025

Journal Articles

Predicting CAR T-cell therapy outcomes in large B-cell lymphoma using pre-infusion clinical and inflammatory markers: A machine learning approach with explainable artificial intelligence

Blood (2025) 146 (Supplement 1): 2569.

https://doi.org/10.1182/blood-2025-2569

Published: 2025

Journal Articles

Venetoclax-based therapy remodels T-cell and NK-cell immunity in patients with chronic lymphocytic leukemia

Blood (2025) 146 (Supplement 1): 5657.

https://doi.org/10.1182/blood-2025-5657

Published: 2025

Journal Articles

Integrated multi-omic profiling identifies molecular subtypes and predicts outcomes in newly diagnosed peripheral T-cell lymphomas

Blood (2025) 146 (Supplement 1): 1758.

https://doi.org/10.1182/blood-2025-1758

Published: 2025

Journal Articles

Assessment of minimal residual disease with droplet digital polymerase chain reaction for BRAF V600E mutation in patients with hairy cell leukemia treated with purine analogs

Gianmarco Favrin, Chiara Varraso, Silvia Zibellini, Emilia Cappello, Virginia Ferretti, Sara Rattotti, Giulia Facchetti, Cristina Picone, Chiara Cavalloni, Martina La Fauci, Beatrice Cuniolo, Luca Arcaini, Marzia Varettoni

Blood (2025) 146 (Supplement 1): 1832.

https://doi.org/10.1182/blood-2025-1832

Published: 2025

Journal Articles

Hbc-positive status for hepatis B virus does not affect CAR-T cell outcomes in lymphoma: Results from the CART-SIE study

Blood (2025) 146 (Supplement 1): 7636.

https://doi.org/10.1182/blood-2025-7636

Published: 2025

Journal Articles

Low vitamin d is an unmodifiable adverse prognostic factor in older DLBCL patients: Results from the previd randomized trial by fondazione italiana linfomi (FIL).

Blood (2025) 146 (Supplement 1): 5462.

https://doi.org/10.1182/blood-2025-5462

Published: 2025

Journal Articles

Integrated clinical and radiomic PET-FLIPI score for risk stratification in newly diagnosed follicular lymphoma

Blood (2025) 146 (Supplement 1): 3561.

https://doi.org/10.1182/blood-2025-3561

Published: 2025

Journal Articles

Checkpoint inhibitors exposure does not affect survival and safety in PMBCL patients receiving CAR T-cells therapy: An analysis of the italian CART-SIE study

Blood (2025) 146 (Supplement 1): 5502.

https://doi.org/10.1182/blood-2025-5502

Published: 2025

Journal Articles

EO2463 (EO) peptide immunotherapy in patients (pts) with newly diagnosed asymptomatic follicular lymphoma (FL) and marginal zone lymphoma (MZL): Study EONHL1-20/sidney (NCT04669171) primary endpoint lugano objective response analysis

Blood (2025) 146 (Supplement 1): 5377.

https://doi.org/10.1182/blood-2025-5377

Published: 2025

Journal Articles

Cytomegalovirus (CMV) reactivation negatively impacts survival after CAR T-cell therapy in lymphoma patients: Results from the CART-SIE study

Blood (2025) 146 (Supplement 1): 3722.

https://doi.org/10.1182/blood-2025-3722

Published: 2025

Journal Articles

Post-transplant lymphoproliferative disorders in adult transplant recipients: Preliminary results of the multicenter italian FIL_PTLD study

Blood (2025) 146 (Supplement 1): 1890.

https://doi.org/10.1182/blood-2025-1890

Published: 2025

Journal Articles

Adding selinexor to ifosfamide, etoposide and desametasone does not improve the outcome in relapsed and refractory peripheral T-cell lymphomas: First report of phase II S-ide study.

Annalisa Chiappella, Anna Dodero, Alessandro Re, Claudia Castellino, Grazia Mallia, Silva Ljevar, Laura Arletti, Luca Arcaini, Pellegrino Musto, Anna Guidetti, Rosalba Miceli, Anisa Bermema, Cristiana Carniti, Paolo Corradini

Blood (2025) 146 (Supplement 1): 1868.

https://doi.org/10.1182/blood-2025-1868

Published: 2025

Journal Articles

Long term follow up of the response adapted FOLL12 trial for patients with advanced stage follicular lymphoma: A study by the fondazione italiana linfomi (FIL).

Blood (2025) 146 (Supplement 1): 1004.

https://doi.org/10.1182/blood-2025-1004

Published: 2025

Journal Articles

Role of allo-HCT in “nonclassical” MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT

Nicola Polverelli, Juan Carlos Hernández-Boluda, Francesco Onida, Carmelo Gurnari, Kavita Raj, Tomasz Czerw, Michelle Kenyon, Marie Robin, Katja Sockel, Annalisa Ruggeri, Isabel Sánchez-Ortega, Daniel A. Arber, Luca Arcaini, Fernando Barroso Duarte, Giorgia Battipaglia, Yves Chalandon, Fabio Ciceri, Nicholas C. P. Cross, Joanna Drozd-Sokolowska, Vaneuza Funke, Nico Gagelmann, Naseema Gangat, Jason Gotlib, Paola Guglielmelli, Claire Harrison, Gabriela Hobbs, Tania Jain, Joseph D. Khoury, Jean Jacques Kiladjian, Nicolaus Kröger, Luca Malcovati, Massimo Martino, Ruben Mesa, Attilio Orazi, Eric Padron, Francesca Palandri, Francesco Passamonti, Mrinal M. Patnaik, Naveen Pemmaraju, Deepti H. Radia, Andreas Reiter, Domenico Russo, Christof Scheid, Ayalew Tefferi, Alessandro M. Vannucchi, Daniel H. Wiseman, Ibrahim Yakoub-Agha, Donal P. McLornan

Blood (2025) 145 (22): 2561–2573.

https://doi.org/10.1182/blood.2024028000

Published: 2025

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial

Final efficacy results of the real-life ambispective urban study on frontline obinutuzumab-based immunochemotherapy for advanced follicular lymphoma

Increased incidence of secondary malignancies after autologous stem cell transplantation in follicular lymphoma patients: Long-term results of the FIL-FLAZ12 Phase III randomized trial

TP53 mutations in paired bone marrow and cell-free DNA samples of patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance prospectively enrolled in the FIL_biowm study of fondazione italiana linfomi

Morphology guided spatial transcriptomics to study topography of Hodgkin reed sternberg cells interaction with tumor microenvironment and its impact in defining risk of progression in classical Hodgkin lymphoma.

EO2463 (EO) peptide immunotherapy combined with rituximab (R) for first-line treatment of low-tumor burden follicular lymphoma (FL): A feasibility evaluation in Study EONHL1-20/sidney (NCT04669171)

Predicting CAR T-cell therapy outcomes in large B-cell lymphoma using pre-infusion clinical and inflammatory markers: A machine learning approach with explainable artificial intelligence

Venetoclax-based therapy remodels T-cell and NK-cell immunity in patients with chronic lymphocytic leukemia

Integrated multi-omic profiling identifies molecular subtypes and predicts outcomes in newly diagnosed peripheral T-cell lymphomas

Assessment of minimal residual disease with droplet digital polymerase chain reaction for BRAF V600E mutation in patients with hairy cell leukemia treated with purine analogs

Hbc-positive status for hepatis B virus does not affect CAR-T cell outcomes in lymphoma: Results from the CART-SIE study

Low vitamin d is an unmodifiable adverse prognostic factor in older DLBCL patients: Results from the previd randomized trial by fondazione italiana linfomi (FIL).

Integrated clinical and radiomic PET-FLIPI score for risk stratification in newly diagnosed follicular lymphoma

Checkpoint inhibitors exposure does not affect survival and safety in PMBCL patients receiving CAR T-cells therapy: An analysis of the italian CART-SIE study

EO2463 (EO) peptide immunotherapy in patients (pts) with newly diagnosed asymptomatic follicular lymphoma (FL) and marginal zone lymphoma (MZL): Study EONHL1-20/sidney (NCT04669171) primary endpoint lugano objective response analysis

Cytomegalovirus (CMV) reactivation negatively impacts survival after CAR T-cell therapy in lymphoma patients: Results from the CART-SIE study

Post-transplant lymphoproliferative disorders in adult transplant recipients: Preliminary results of the multicenter italian FIL_PTLD study

Adding selinexor to ifosfamide, etoposide and desametasone does not improve the outcome in relapsed and refractory peripheral T-cell lymphomas: First report of phase II S-ide study.

Long term follow up of the response adapted FOLL12 trial for patients with advanced stage follicular lymphoma: A study by the fondazione italiana linfomi (FIL).

Role of allo-HCT in “nonclassical” MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only